Advertisement

Octreotide Injection

[28 June 2016]

Products Affected - Description

Octreotide Acetate injection, Fresenius Kabi
50 mcg/mL, 1 mL vial, 10 count (NDC 63323-0365-01)
500 mcg/mL, 1 mL vial, 10 count (NDC 63323-0377-01)
 
Octreotide Acetate injection, Sagent
200 mcg/mL, 5 mL vial, 1 count (NDC 25021-0454-05)
500 mcg/mL, 1 mL vial, 10 count (NDC 25021-0453-01)
 
Octreotide Acetate injection, Sun Pharma
50 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0348-44)
100 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0349-44)
200 mcg/mL, 5 mL vial, 1 count (NDC 62756-0350-40)
500 mcg/mL, 1 mL ampule, 10 count (NDC 62756-0351-44)
1000 mcg/mL, 5 mL vial, 1 count (NDC 62756-0352-40)
 
Octreotide Acetate injection, Teva
50 mcg/mL, 1 mL vial, 25 count (NDC 00703-3301-04)

Reason for the Shortage

  • Fresenius Kabi did not provide a reason for the shortage.
  • Sagent has octreotide on shortage due to manufacturing delays.
  • Teva is relaunching several presentations this year.
  • Sun Pharm did not provide a reason for the shortage.

Available Products

Sandostatin injection, Novartis
50 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0180-01)
100 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0181-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 00078-0183-25)
500 mcg/mL, 1 mL ampule, 10 count (NDC 00078-0182-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00078-0184-25)
 
Octreotide Acetate injection, Fresenius Kabi
100 mcg/mL, 1 mL vial, 10 count (NDC 63323-0376-01)
200 mcg/mL, 5 mL vial, 1 count (NDC 63323-0378-05)
1000 mcg/mL, 5 mL vial, 1 count (NDC 63323-0379-05)
 
Octreotide Acetate injection, Mylan Institutional
50 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0239-01)
100 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0245-01)
500 mcg/mL, 1 mL syringe, 10 count (NDC 67457-0246-01)
 
Octreotide Acetate injection, Sagent
50 mcg/mL, 1 mL vial, 10 count (NDC 25021-0451-01)
100 mcg/mL, 1 mL vial, 10 count (NDC 25021-0452-01)
1000 mcg/mL, 5 mL vial, 1 count (NDC 25021-0455-05)
 
Octreotide Acetate injection, Teva
100 mcg/mL, 1 mL vial, 25 count (NDC 00703-3311-04)
200 mcg/mL, 5 mL vial, 1 count (NDC 00703-3333-01)
500 mcg/mL, 1 mL vial, 25 count (NDC 00703-3321-04)
1000 mcg/mL, 5 mL vial, 1 count (NDC 00703-3343-01)

Estimated Resupply Dates

  • Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company cannot estimate a release date. Octreotide 500 mcg/mL 1 mL vials are on back order and the company estimates a release date in late-June 2016.
  • Sagent has octreotide 200 mcg/mL 5 mL vials and 500 mcg/mL 1 mL vials on allocation.
  • Sun Pharma cannot provide availability information at this time.
  • Teva is relaunching octreotide and the 50 mcg/mL 1 mL vials have an estimated relaunch date of late-July 2016. The other vials are available.

Related Shortages

Updated

June 28, May 27, 20 and 17, April 14 and 13, March 16, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing